Allergy Relief(Diphenhydramin) (diphenhydramine HCl)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Diphenhydramine is an ethanolamine-derivative, first generation antihistamine.
Diphenhydramine shares the actions and uses of other antihistamines.
Generic name: diphenhydramine HCl
Pronunciation: (DYE-fen-HYE-dra-meen)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Allergy Relief(Diphenhydramin)
Indications
The following indications are listed for Allergy Relief(Diphenhydramin):
- Allergic Conjunctivitis
- Allergic Reaction
- Allergic Rhinitis
- Anaphylaxis
- Cough
- Dermatographic Urticaria
- Idiopathic Parkinsonism
- Insomnia
- Motion Sickness
- Nasal Congestion
- Nausea
- Nausea And Vomiting
- Parkinsonism
- Pruritus Of Skin
- Sneezing
- Urticaria
- Vertigo
- Vomiting
Also known as: Agrypnia, Ahypnia, Allergy Eye Itch, Anaphylactic Reaction, Atopic Conjunctivitis, Autographism, Cnidosis, Dermatography, Dermographia, Dermographism, Dermography, Ebbecke's Reaction, Emesis, Factitious Urticaria, Itching Wheals, Itchy Eyes Due To Allergies, Itchy Skin Eruption, Nasal Stuffiness, Nettle Rash, Ocular Itching Due To Allergies, Paralysis Agitans, Primary Parkinson's Disease, Pruritic Dermatitis, Queasy, Riders' Vertigo, Severe Type I Hypersensitivity Reaction, Skin Writing, Trembling Palsy, Uredo, Urticaria Factitia, Urticarial Rash, Urtication, Vomit, Weal.
Dosing
Dosage should be individualized according to the patient's response and tolerance.
Diphenhydramine hydrochloride usually is administered orally.
Diphenhydramine citrate usually is administered orally.
When oral therapy is not feasible, diphenhydramine hydrochloride may be given by deep IM or, preferably, IV injection. The drug should not be given subcutaneously, intradermally, or perivascularly because of its irritating effects; local necrosis has been reported following subcutaneous or intradermal administration of parenteral diphenhydramine. IV use of the drug in a home-care setting should be employed under careful supervision. Use of diphenhydramine for local anesthesia via local infiltration is discouraged because of the risk of local tissue necrosis. Diphenhydramine hydrochloride should not be given to premature or full-term neonates. (See Cautions: Pediatric Precautions.)
For the temporary relief of pruritus associated with various skin conditions and disorders, diphenhydramine hydrochloride-containing preparations are applied topically in the form of a cream, lotion, or topical solution. The possibility of clinically important percutaneous absorption of the drug following topical application should be considered. (See Cautions.)
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in rats and rabbits receiving diphenhydramine hydrochloride dosages up to 5 times the recommended human dosage have not revealed evidence of harm to the fetus. However, diphenhydramine has been shown to cross the placenta. In one epidemiologic study, use of bromodiphenhydramine (no longer commercially available) but not diphenhydramine was associated with an increased risk of teratogenic effects. In another epidemiologic study, there also was no evidence of increased risk of teratogenicity associated with diphenhydramine use during the first trimester, although a modest association could not be ruled out. Use of diphenhydramine during the first trimester of pregnancy has been associated with an increased risk of cleft palate alone or combined with other fetal abnormalities, and the drug has been reported to potentiate the teratogenic effect of morphine in mice. The manufacturers state that there are no adequate and controlled studies to date using diphenhydramine in pregnant women, and the drugs should be used during pregnancy only when clearly needed.
Diphenhydramine has been detected in milk. Because of the potential for serious adverse reactions to antihistamines in nursing infants, a decision should be made whether to discontinue nursing or diphenhydramine, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.